Clinical Trials Directory

Trials / Completed

CompletedNCT03596346

Evaluation of Safety and Tolerability of a Rapeseed Food Ingredient

Evaluation of Safety and Tolerability of a Rapeseed Food Ingredient Among Generally Healthy Consumers - A Randomized Double-blind, Controlled Parallel-group Four-week Intervention Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
54 (actual)
Sponsor
Avena Nordic Grain Oy · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

The study is designed to assess the safety and tolerability of a novel food ingredient produced from rape seeds supplied as a snack-bar in a 4-week controlled intervention.

Detailed description

An 4-week randomized, double-blind, controlled, parallel-group intervention for assessment of safety and tolerability of a novel rape seed ingredient (RI) followed by a 2-week follow-up period. Baseline measures for digestive symptom frequency questionnaire (DSFQ), blood safety tests and body mass index (BMI) will be collected at screening visit. At the randomization visit, participants' eligibility will be confirmed, and they will be randomly allocated into 2 parallel groups consuming either 20 g (test group) or 0 g (control group) of RI within 2 daily snack bars. During the intervention and follow-up periods participants will bi-weekly respond to a GI symptom questionnaire including DSFQ, stool frequency and stool consistency, and palatability items. At the end of the intervention period (week 4) a clinic visit including BMI and AE recording and blood safety tests will be held.

Conditions

Interventions

TypeNameDescription
OTHERRapeseed ingredient (RI)2 snack bars daily containing 10 g of RI each.
OTHERControl product without added RI2 snack bars daily containing 0 g of RI.

Timeline

Start date
2018-07-04
Primary completion
2018-10-25
Completion
2018-10-25
First posted
2018-07-23
Last updated
2018-11-30

Locations

1 site across 1 country: Finland

Source: ClinicalTrials.gov record NCT03596346. Inclusion in this directory is not an endorsement.